Literature DB >> 16330577

In vivo evaluation and dosimetry of 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model.

Veerle Kersemans1, Bart Cornelissen, Klaus Bacher, Ken Kersemans, Hubert Thierens, Rudi A Dierckx, Bart De Spiegeleer, Guido Slegers, John Mertens.   

Abstract

UNLABELLED: Earlier reports described the preferential uptake of d-amino acids in tumor-bearing mice. Moreover, it was shown that in tumor cells in vitro the L-amino acid transporter system seemed to lack stereospecificity. Because of the successful results with 123/125I-2-iodo-L-phenylalanine, 123/125I-2-iodo-D-phenylalanine was developed, and its tumor-detecting characteristics were evaluated in vivo.
METHODS: 123I labeling of 2-iodo-D-phenylalanine was performed with a kit formulation by use of Cu1+-assisted nucleophilic exchange. 123I-2-Iodo-D-phenylalanine was evaluated in R1M tumor-bearing athymic mice by dynamic planar imaging (DPI) and dissection. The in vivo stability of the tracer was tested by high-performance liquid chromatography. Tumor tracer retention and tracer contrast were evaluated as a function of time. Two-compartment blood modeling from DPI results and dosimetric calculations from biodistribution results were carried out. Moreover, 125I-2-iodo-D-phenylalanine and 18F-FDG uptake in acute inflammation was investigated.
RESULTS: 123I-2-Iodo-D-phenylalanine was metabolically stable. Fast, high, and specific tumor retention was observed. Two-compartment modeling confirmed the fast clearance of the tracer through the kidneys to the bladder, as observed by DPI and dissection. Moreover, compared with the L-isomer, 123I-2-iodo-D-phenylalanine demonstrated faster clearance and faster uptake in the peripheral compartment. No accumulation in the abdomen or in the brain was noted. Dosimetry revealed that 123I-2-iodo-D-phenylalanine demonstrated a low radiation burden comparable to those of 123I-2-iodo-L-phenylalanine and 123I-2-iodo-L-tyrosine. Although 123I-2-iodo-D-phenylalanine showed a tumor retention of only 4%, the tumor contrast was increased up to 350% at 19 h after injection.
CONCLUSION: 123I-2-Iodo-D-phenylalanine is a promising tracer for diagnostic oncologic imaging because of its high, fast, and specific tumor uptake and fast clearance from blood.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330577

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

1.  An alternative and expedient synthesis of radioiodinated 4-iodophenylalanine.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Linda Grasfeder; Michael R Zalutsky; Bennett Chin
Journal:  Appl Radiat Isot       Date:  2011-05-19       Impact factor: 1.513

2.  Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.

Authors:  Chang-Lae Lee; Hilla Wahnishe; George A Sayre; Hyo-Min Cho; Hee-Joung Kim; Miguel Hernandez-Pampaloni; Randall A Hawkins; Shorouk F Dannoon; Henry F VanBrocklin; Melissa Itsara; William A Weiss; Xiaodong Yang; Daphne A Haas-Kogan; Katherine K Matthay; Youngho Seo
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

3.  Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging.

Authors:  Chaofeng Huang; Liya Yuan; Keith M Rich; Jonathan McConathy
Journal:  Nucl Med Biol       Date:  2013-03-23       Impact factor: 2.408

4.  Evaluation of 3-l- and 3-d-[18F]Fluorophenylalanines as PET Tracers for Tumor Imaging.

Authors:  Felicia Krämer; Benedikt Gröner; Chris Hoffmann; Austin Craig; Melanie Brugger; Alexander Drzezga; Marco Timmer; Felix Neumaier; Boris D Zlatopolskiy; Heike Endepols; Bernd Neumaier
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.